Quoin Pharmaceuticals
QNRX
19 hedge funds and large institutions have $12.2M invested in Quoin Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
113,330% more capital invested
Capital invested by funds: $10.7K → $12.2M (+$12.2M)
280% more funds holding
Funds holding: 5 → 19 (+14)
143.04% more ownership
Funds ownership: 0.25% → 143.3% (+143%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.88M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.08M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.06M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$1.02M |
| 5 |
Millennium Management
New York
|
+$1.02M |
Top Sellers
QNRX Hedge Fund Activity: Q4 2025 in Review
19 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q4 2025, worth a combined $12.2M — up 113,330% from $10.7K a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new QNRX positions and 0 closed out — a net gain of 14 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.88M.
- 19 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q4 2025, up from 5 in Q3 2025.
- Funds reported $12.2M of Quoin Pharmaceuticals stock for Q4 2025, up 113,330% quarter-over-quarter.
- 14 funds opened new Quoin Pharmaceuticals positions in Q4 2025 and 0 closed out, a net change of +14 holders.
- The largest Quoin Pharmaceuticals buyer in Q4 2025 was Ikarian Capital, an estimated $2.88M added.
Based on aggregated 13F filings for Q4 2025.